文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气心脑血管急症

COVID-19患者静脉-静脉体外膜氧合期间的脑血管并发症

Cerebrovascular Complications of COVID-19 on Venovenous Extracorporeal Membrane Oxygenation.
PubMed 文献 · Crit Care Med · 2023-04-03
一句话结论COVID-19静脉-静脉ECMO患者卒中发生率7.2%,其中83.7%为出血性;肥胖、ECMO前使用血管升压药及ECMO启动48小时内PaCO2相对下降和适度高氧与卒中风险增加相关。

该研究基于COVID-19危重症协作组(COVID Critical)登记数据库,覆盖53个国家380家机构,纳入595例接受静脉-静脉ECMO支持的成人COVID-19患者,分析卒中的发生率和危险因素。结果显示43例(7.2%)发生卒中,其中83.7%为出血性。多变量生存分析显示,肥胖(aHR 2.19;95%CI 1.05-4.59)和ECMO前使用血管升压药(aHR 2.37;95%CI 1.08-5.22)与卒中风险增加相关。卒中患者ECMO启动后48小时相对ΔPaCO2为-26%、相对ΔPaO2为+24%,而非卒中组分别为-17%和+7%。卒中患者院内死亡率为79%,无卒中患者为45%。

要点

  • COVID-19静脉-静脉ECMO患者卒中发生率为7.2%(43/595),其中83.7%为出血性卒中。
  • 肥胖(aHR 2.19;95%CI 1.05-4.59)和ECMO前使用血管升压药(aHR 2.37;95%CI 1.08-5.22)与卒中风险增加独立相关。
  • 卒中患者ECMO启动后48小时相对ΔPaCO2为-26%、相对ΔPaO2为+24%,非卒中组分别为-17%和+7%。
  • 发生急性卒中的患者院内死亡率为79%,无卒中患者为45%。

适用人群与场景

  • 成人COVID-19患者,接受静脉-静脉ECMO支持。
  • 数据来源为COVID-19危重症协作组(COVID Critical)登记数据库,覆盖53个国家380家机构。

研究设计与关键结果

  • 研究设计:前瞻性收集的观察性数据,采用单变量和多变量生存模型分析卒中危险因素,使用Cox比例风险模型和Fine-Gray模型,以死亡和出院作为竞争风险。
  • 样本量:595例接受静脉-静脉ECMO支持的成人COVID-19患者,中位年龄51岁(四分位距42-59岁),男性占70.8%。
  • 主要终点:43例(7.2%)发生卒中,其中83.7%为出血性卒中。
  • 多变量生存分析:肥胖与卒中风险增加相关(aHR 2.19;95%CI 1.05-4.59);ECMO前使用血管升压药与卒中风险增加相关(aHR 2.37;95%CI 1.08-5.22)。
  • 卒中患者ECMO启动后48小时相对ΔPaCO2为-26%,相对ΔPaO2为+24%;非卒中组相对ΔPaCO2为-17%,相对ΔPaO2为+7%。
  • 院内死亡率:卒中患者为79%,无卒中患者为45%。

证据类型、等级与局限

  • 证据类型:前瞻性收集的观察性数据,基于多国登记数据库(COVID-19危重症协作组,COVID Critical)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,肥胖和ECMO前使用血管升压药与COVID-19静脉-静脉ECMO患者卒中发生相关。
  • 作者认为,ECMO启动后48小时内PaCO2相对下降和适度高氧是卒中的额外危险因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Evidence of cerebrovascular complications in COVID-19 requiring venovenous extracorporeal membrane oxygenation (ECMO) is limited. Our study aims to characterize the prevalence and risk factors of stroke secondary to COVID-19 in patients on venovenous ECMO.

DESIGN: We analyzed prospectively collected observational data, using univariable and multivariable survival modeling to identify risk factors for stroke. Cox proportional hazards and Fine-Gray models were used, with death and discharge treated as competing risks.

SETTING: Three hundred eighty institutions in 53 countries in the COVID-19 Critical Care Consortium (COVID Critical) registry.

PATIENTS: Adult COVID-19 patients who were supported by venovenous ECMO.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Five hundred ninety-five patients (median age [interquartile range], 51 yr [42-59 yr]; male: 70.8%) had venovenous ECMO support. Forty-three patients (7.2%) suffered strokes, 83.7% of which were hemorrhagic. In multivariable survival analysis, obesity (adjusted hazard ratio [aHR], 2.19; 95% CI, 1.05-4.59) and use of vasopressors before ECMO (aHR, 2.37; 95% CI, 1.08-5.22) were associated with an increased risk of stroke. Forty-eight-hour post-ECMO Pa co2 -pre-ECMO Pa co2 /pre-ECMO Pa co2 (relative ΔPa co2 ) of negative 26% and 48-hour post-ECMO Pa o2 -pre-ECMO Pa o2 /pre-ECMO Pa o2 (relative ΔPa o2 ) of positive 24% at 48 hours of ECMO initiation were observed in stroke patients in comparison to relative ΔPa co2 of negative 17% and relative ΔPa o2 of positive 7% in the nonstroke group. Patients with acute stroke had a 79% in-hospital mortality compared with 45% mortality for stroke-free patients.

CONCLUSIONS: Our study highlights the association of obesity and pre-ECMO vasopressor use with the development of stroke in COVID-19 patients on venovenous ECMO. Also, the importance of relative decrease in Pa co2 and moderate hyperoxia within 48 hours after ECMO initiation were additional risk factors.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Zaaqoq AM, Griffee MJ, Kelly TL, et al. Cerebrovascular Complications of COVID-19 on Venovenous Extracorporeal Membrane Oxygenation. Crit Care Med. 2023. PMID: 37010526. doi:10.1097/CCM.0000000000005861

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。